The Zhitong Finance App learned that DBS released a research report saying that Longfeng Group (02290.HK) is the largest pharmaceutical retailer in Hong Kong in terms of retail sales, with a market share of 5.2% in fiscal year 2025, ranking third in pharmaceuticals, health and beauty, with a market share of 5.8%. For the first time, it covered a “buy” rating, with a target price of HK$7.98.

The Zhitong Finance App learned that DBS released a research report saying that Longfeng Group (02290.HK) is the largest pharmaceutical retailer in Hong Kong in terms of retail sales, with a market share of 5.2% in fiscal year 2025, ranking third in pharmaceuticals, health and beauty, with a market share of 5.8%. For the first time, it covered a “buy” rating, with a target price of HK$7.98.